Daiichi Sankyo Prioritizes R&D On Thrombosis And Three Other Areas
This article was originally published in PharmAsia News
Daiichi Sankyo unveiled a new business strategy at an Oct. 8 conference in Tokyo. The strategy includes prioritizing research and development resources to antibody drug denosumab and CS-8635, a three-drug combination hypertension treatment. The company has identified four research areas as growth engines to focus R&D resources: thrombosis, cancer, diabetes and arthritis. In the thrombosis area, the company plans to focus on antiplalelet and anticlotting drugs. Oral anti-Xa drug DU-176b has completed Phase II trials in Japan, Europe and the U.S., and international joint Phase III trials will start in November. At the meeting, Daiichi Sankyo also disclosed the company's decision to halt developing antiplatelet drug DZ-697b. (Click here for more - Japanese language
You may also be interested in...
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.
With many competitor programs on hold during the COVID crisis, L’Oreal dialed up its media investments and launched products over the summer that were postponed from the first quarter, resulting in a return to growth in the firm’s third quarter led by Professional Products and Active Cosmetics.
Just as the MDR and IVDR are being implemented, increasing regulatory divergence in Europe is a growing danger to patient safety throughout the EU. Erik Raadsheer, senior director of Align Technology, expressed concerns.